

ERIS PHARMA GmbH
BALANCE SHEET AS AT MARCH 31, 2023

		Amount in EUR	
		31-Mar-23	31-Mar-22
A ASSETS			
I Non-current assets			
(a) Other intangible assets		14,400	2,797
(b) Intangibles assets under development		-	26,884
Total non-current assets		14,400	29,681
I Current assets			
(a) Inventories		-	90,416
(b) Financial assets			
(i) Trade receivables	1	-	0.20
(ii) Cash and cash equivalents	2	682	5,075
(c) Other current assets	3	46,024	41,166
Total current assets		46,706	136,658
TOTAL ASSETS		61,105	166,339
B EQUITY AND LIABILITIES			
I Equity			
(a) Equity share capital	4	25,000	25,000
(b) Other equity	5	(480,956)	(297,165)
Total Equity		(455,956)	(272,165)
II Current liabilities			
(a) Financial liabilities			
(i) Borrowings		283,574	229,304
(ii) Trade payables	6	138,638	54,672
(iii) Other financial liabilities	7	94,849	154,528
Total current liabilities		517,061	438,504
TOTAL EQUITY AND LIABILITIES		61,105	166,339

ERIS PHARMA GmbH
STATEMENT OF PROFIT AND LOSS FOR THE YEAR ENDED MARCH 31, 2023

Particulars	Note No.	Amount in EUR	
		31-Mar-23	31-Mar-22
1 Revenue from operations	8	5,062	180,505
2 Other Income		-	829
3 Total Revenue (1+2)		5,062	181,334
4 Expenses			
(a) Cost of Goods sold	9	90,417	87,712
(b) Finance costs	10	11,624	15,783
(c) Depreciation and amortisation expense		36,944	12,169
(d) Other expenses	11	49,867	71,371
Total expenses		188,852	187,035
5 Profit / (Loss) before exceptional items and taxes (3-4)		(183,790)	(5,701)
6 Exceptional Item		-	-
7 Profit / (Loss) before taxes (5+6)		(183,790)	(5,701)
8 Tax Expense:			
(1) Current tax		-	-
(2) Deferred tax		-	-
Total tax expenses		-	-
9 Profit / (Loss) for the year after tax		(183,790)	(5,701)

ERIS PHARMA GmbH
Notes forming part of financial statement

Note

No.

		Amount in EUR	
		31-Mar-23	31-Mar-22
1	Trade receivables		
	Particulars	31-Mar-23	31-Mar-22
	Unsecured		
	Considered good	-	0.20
	Considered doubtful		
		-	0.20
	Less: Allowance for doubtful trade receivables		
	Total	-	0.20
2	Cash and cash equivalents		
	Particulars	31-Mar-23	31-Mar-22
	Cash in hand	-	-
	Balances with banks:		
	In current accounts	682	5,075
	Total	682	5,075
3	Other current assets		
	Particulars	31-Mar-23	31-Mar-22
	Unsecured, considered good		
	Balances with government authorities:		
	- Vat refund receivable	41,945	36,259
	Prepaid Expenses	4,079	4,908
	Total	46,024	41,166
4	Share capital		
	Particulars	31-Mar-23	31-Mar-22
	Issued, subscribed and fully paid-up		
	Equity share capital	25,000	25,000
	Total	25,000	25,000
5	Reserves and surplus		
	Particulars	31-Mar-23	31-Mar-22
	Surplus in statement of profit and loss		
	Opening balance	(297,165)	(257,700)
	Add: Profit / (Loss) for the year	(183,790)	(39,466)
	Closing balance	(480,956)	(297,165)
	Total	(480,956)	(297,165)
6	Trade payables		
	Particulars	31-Mar-23	31-Mar-22
	Trade payable	138,638	54,672
	Total	138,638	54,672
7	Other Current financial Liabilities		
	Particulars	31-Mar-23	31-Mar-22
	Interest accrued but not due	-	42,804
	Advance from Customers	94,849	111,724
	Total	94,849	154,528

ERIS PHARMA GmbH

Notes forming part of financial statement

Note

No.

8 Revenue from operations	Amount in EUR	
Particulars	31-Mar-23	31-Mar-22
Sale of Product	-	-
Other Income (Operations)	5,062	87,383
Total	5,062	87,383

9 Cost of goods sold	Amount in EUR	
Particulars	31-Mar-23	31-Mar-22
Opening stock	90,416	115,597
Add: Purchases	-	-
Closing stock	(1)	90,416
Total	90,417	25,181

10 Finance cost	Amount in EUR	
Particulars	31-Mar-23	31-Mar-22
Finance Charges	11,624	10,403
Total	11,624	10,403

11 Other expenses	Amount in EUR	
Particulars	31-Mar-23	31-Mar-22
Freight and forwarding	24,975	37,050
Rent	6,478	7,054
Rates & taxes	164	1,785
Repairs & Maintenance	1,291	113
Insurance	5,810	3,008
Communication expenses	448	528
Legal expenses	3,078	172
Professional fees	358	492
Payment to Auditors - For Statutory Audit	-	4,741
Miscellaneous Expense	7,264	966
Total	49,867	55,907